<DOC>
	<DOC>NCT02608515</DOC>
	<brief_summary>This non-interventional retrospective chart review study aims to evaluate the clinical outcomes of patients with RRMM receiving lenalidomide/dexamethasone (Len/Dex) treatment at 1st relapse and the treatment patterns following progressive disease as part of the routine clinical practice in Greece.</brief_summary>
	<brief_title>A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Subjects must fulfill ALL of the following criteria: Subjects of both genders, aged 18 years or older Subjects must have a relapsed or refractory MM diagnosis according to IMWG or EBMT criteria Subjects must have initiated secondline therapy with lenalidomide/dexamethasone according to the approved products' Summary of Product Characteristics (SmPC) between 01 January 2009 and 01 March 2014 Subjects must have available medical files/records and detailed historical data on their disease course and clinical management Provision of signed ICF for collecting and analyzing medical data pertinent to the objectives of this study For the candidate subjects NONE of the following criteria should apply: Prior malignancy (within the 3 years preceding initial diagnosis of MM) Concurrent administration of anticancer regimens for malignancies other than MM between the time of initial MM diagnosis and time of second relapse Subject participation in an interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>